Drug Profile
Celgosivir - 60 Degree Pharmaceutical Australia
Alternative Names: 6-O-Butanoylcastanospermine; 60P 001; BuCast™; celgosivir hydrochloride; MBI-3253; MDL 28574; MDL 28574A; MX-3253; VIR 222Latest Information Update: 08 Apr 2021
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Developer 60 Degrees Pharmaceuticals Australia; Carrus Capital Corporation; Duke-NUS Graduate Medical School Singapore; Singapore General Hospital
- Class Antivirals; Indolizines; Small molecules
- Mechanism of Action Alpha-glucosidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Dengue
- Discontinued Hepatitis C; HIV infections
Most Recent Events
- 08 Apr 2021 Celgosivir is still in phase I/II trials for Dengue in Singapore (60 Degree Pharmaceuticals pipeline, March 2021)
- 08 Apr 2021 60 degree pharmaceutical Australia planning to fulfil the US FDA priority review voucher (PRV) criteria (60 degree pharmaceutical Australia pipeline, march 2021)
- 08 Apr 2021 60 Degrees Pharmaceuticals plans a phase II trial for Dengue (60 degree pharmaceutical Australia pipeline, march 2021)